Affinity Asset Advisors
Latest statistics and disclosures from Affinity Asset Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INSM, VRNA, SPY, XENE, MDGL, and represent 28.42% of Affinity Asset Advisors's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$56M), INSM (+$26M), ABVX (+$22M), MRUS (+$20M), CYTK (+$19M), APGE (+$19M), MDGL (+$16M), SYRE (+$14M), SLNO (+$14M), XENE (+$12M).
- Started 23 new stock positions in RVMD, MIST, EPRX, CYTK, OCUL, ATYR, CLDX, INSP, OBIO, Nextcure. UTHR, Celcuity, SMMT, IMVT, SPY, SLNO, SPRY, CMPS, DNTH, NTLA, TARS, SGMT, MBX.
- Reduced shares in these 10 stocks: BPMC (-$32M), PTGX (-$15M), TVTX (-$11M), AMGN (-$11M), CRSP (-$9.7M), VERA (-$7.0M), INZY (-$7.0M), MLYS (-$5.7M), AXSM (-$5.2M), BBIO.
- Sold out of its positions in ALT, AMGN, AXSM, BPMC, CAPR, GALT, INMB, INZY, MIRM, NXTC. NKTX, NVAX, OKUR, RADX, RAPP, THRD, CRSP, IMTXW.
- Affinity Asset Advisors was a net buyer of stock by $213M.
- Affinity Asset Advisors has $1.1B in assets under management (AUM), dropping by 56.79%.
- Central Index Key (CIK): 0001773195
Tip: Access up to 7 years of quarterly data
Positions held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Affinity Asset Advisors
Affinity Asset Advisors holds 93 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Insmed Com Par $.01 (INSM) | 8.2 | $94M | +37% | 655k | 144.01 |
|
| Verona Pharma Sponsored Ads (VRNA) | 5.8 | $67M | +2% | 625k | 106.71 |
|
| Spdr S&p 500 Etf Tr Tr Unit (SPY) | 4.9 | $56M | NEW | 85k | 666.18 |
|
| Xenon Pharmaceuticals (XENE) | 4.9 | $56M | +27% | 1.4M | 40.15 |
|
| Madrigal Pharmaceuticals (MDGL) | 4.6 | $53M | +43% | 115k | 458.66 |
|
| Apogee Therapeutics (APGE) | 4.1 | $47M | +68% | 1.2M | 39.73 |
|
| Arcellx Common Stock (ACLX) | 3.6 | $41M | 500k | 82.10 |
|
|
| Alkermes SHS (ALKS) | 3.3 | $38M | +25% | 1.3M | 30.00 |
|
| Nuvalent Inc-a (NUVL) | 2.9 | $33M | -7% | 384k | 86.48 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.7 | $31M | +260% | 360k | 84.90 |
|
| Mineralys Therapeutics (MLYS) | 2.5 | $28M | -16% | 750k | 37.92 |
|
| Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 2.5 | $28M | 1.4M | 20.20 |
|
|
| Merus N V (MRUS) | 2.3 | $27M | +308% | 286k | 94.15 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.3 | $27M | +22% | 1.1M | 24.25 |
|
| Lexeo Therapeutics (LXEO) | 2.2 | $26M | +7% | 3.9M | 6.64 |
|
| Trevi Therapeutics (TRVI) | 2.2 | $26M | +10% | 2.8M | 9.15 |
|
| Spyre Therapeutics Com New (SYRE) | 2.1 | $24M | +133% | 1.4M | 16.76 |
|
| Exelixis Put Option (EXEL) | 1.8 | $21M | -16% | 500k | 41.30 |
|
| Rezolute Com New (RZLT) | 1.7 | $20M | -4% | 2.1M | 9.40 |
|
| Cytokinetics Com New (CYTK) | 1.7 | $19M | NEW | 350k | 54.96 |
|
| Oruka Therapeutics (ORKA) | 1.6 | $18M | +58% | 959k | 19.23 |
|
| Uniqure Nv SHS (QURE) | 1.5 | $18M | +27% | 300k | 58.37 |
|
| Wave Life Sciences SHS (WVE) | 1.3 | $15M | +4% | 2.1M | 7.32 |
|
| Protagonist Therapeutics (PTGX) | 1.3 | $15M | -49% | 221k | 66.43 |
|
| Soleno Therapeutics (SLNO) | 1.2 | $14M | NEW | 200k | 67.60 |
|
| Avalo Therapeutics Com New (AVTX) | 1.1 | $13M | +65% | 1.0M | 12.71 |
|
| Establishment Labs Holdings Ord (ESTA) | 1.1 | $13M | -7% | 310k | 40.99 |
|
| Karyopharm Therapeutics Note 3.000%10/1 (Principal) | 1.1 | $13M | 15M | 0.82 |
|
|
| Ventyx Biosciences (VTYX) | 1.1 | $12M | -13% | 3.9M | 3.11 |
|
| Roivant Sciences SHS (ROIV) | 1.1 | $12M | +100% | 800k | 15.13 |
|
| Travere Therapeutics (TVTX) | 1.0 | $12M | -48% | 500k | 23.90 |
|
| Dianthus Therapeutics (DNTH) | 0.9 | $10M | NEW | 262k | 39.35 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.9 | $9.8M | +1400% | 3.0M | 3.27 |
|
| Erasca (ERAS) | 0.8 | $9.3M | +4% | 4.3M | 2.18 |
|
| Nurix Therapeutics (NRIX) | 0.8 | $8.9M | 968k | 9.24 |
|
|
| Vera Therapeutics Cl A (VERA) | 0.8 | $8.8M | -44% | 303k | 29.06 |
|
| Enliven Therapeutics (ELVN) | 0.7 | $8.2M | 400k | 20.47 |
|
|
| Travere Therapeutics Note 2.250% 3/0 (Principal) | 0.7 | $7.9M | 7.0M | 1.13 |
|
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.7 | $7.8M | 275k | 28.44 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.7 | $7.8M | NEW | 300k | 25.87 |
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.7 | $7.7M | +2% | 3.6M | 2.13 |
|
| Tarsus Pharmaceuticals (TARS) | 0.6 | $7.4M | NEW | 125k | 59.43 |
|
| Summit Therapeutics Put Option (SMMT) | 0.6 | $7.2M | NEW | 350k | 20.66 |
|
| Akebia Therapeutics (AKBA) | 0.6 | $6.7M | +25% | 2.5M | 2.73 |
|
| Monopar Therapeutics Com New (MNPR) | 0.6 | $6.5M | +17% | 80k | 81.67 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.5 | $5.5M | +470% | 1.3M | 4.33 |
|
| Miragen Therapeutics (VRDN) | 0.5 | $5.4M | -35% | 250k | 21.58 |
|
| Savara (SVRA) | 0.5 | $5.4M | +200% | 1.5M | 3.57 |
|
| Intellia Therapeutics Call Option (NTLA) | 0.5 | $5.2M | NEW | 300k | 17.27 |
|
| Olema Pharmaceuticals (OLMA) | 0.4 | $4.9M | +100% | 500k | 9.79 |
|
| Immunovant (IMVT) | 0.4 | $4.8M | NEW | 300k | 16.12 |
|
| Omeros Corp Note 9.500% 6/1 (Principal) | 0.4 | $4.7M | -38% | 5.5M | 0.85 |
|
| Revolution Medicines (RVMD) | 0.4 | $4.7M | NEW | 100k | 46.70 |
|
| Omeros Corporation Put Option (OMER) | 0.4 | $4.6M | +261% | 1.1M | 4.10 |
|
| Vaxcyte (PCVX) | 0.4 | $4.5M | 125k | 36.02 |
|
|
| Newamsterdam Pharma Company *w Exp 99/99/999 (NAMSW) | 0.4 | $4.2M | 245k | 17.11 |
|
|
| Celcuity Note 2.750% 8/0 (Principal) | 0.3 | $4.0M | NEW | 3.0M | 1.33 |
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.3 | $3.8M | 350k | 10.73 |
|
|
| Inspire Med Sys (INSP) | 0.3 | $3.7M | NEW | 50k | 74.20 |
|
| Ovid Therapeutics (OVID) | 0.3 | $3.4M | +296% | 2.7M | 1.30 |
|
| Bridgebio Pharma (BBIO) | 0.3 | $3.4M | -56% | 65k | 51.94 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 0.3 | $3.3M | 25k | 131.80 |
|
|
| Crinetics Pharmaceuticals In (CRNX) | 0.3 | $3.1M | -50% | 75k | 41.65 |
|
| Mbx Biosciences (MBX) | 0.3 | $2.9M | NEW | 165k | 17.50 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.2 | $2.9M | -42% | 1.8M | 1.63 |
|
| Ocular Therapeutix (OCUL) | 0.2 | $2.8M | NEW | 239k | 11.69 |
|
| Oaktree Acquisition Corp Iii Unit 10/04/2029 (OACCU) | 0.2 | $2.7M | 250k | 10.64 |
|
|
| Eliem Therapeutics (CLYM) | 0.2 | $2.6M | -13% | 1.3M | 2.01 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.2 | $2.4M | NEW | 350k | 6.86 |
|
| Astria Therapeutics (ATXS) | 0.2 | $2.2M | 300k | 7.28 |
|
|
| United Therapeutics Corporation (UTHR) | 0.2 | $2.1M | NEW | 5.0k | 419.21 |
|
| Geron Corporation (GERN) | 0.2 | $2.1M | 1.5M | 1.37 |
|
|
| Anteris Technologies Global (AVR) | 0.2 | $2.0M | +5% | 450k | 4.50 |
|
| Health Sciences Acq Corp 2 (OBIO) | 0.2 | $1.8M | NEW | 727k | 2.48 |
|
| Eupraxia Pharmaceuticals (EPRX) | 0.2 | $1.8M | NEW | 300k | 5.90 |
|
| Cullinan Oncology (CGEM) | 0.1 | $1.6M | 264k | 5.93 |
|
|
| Atyr Pharma Com New Put Option (ATYR) | 0.1 | $1.5M | NEW | 2.1M | 0.72 |
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $1.3M | NEW | 667k | 2.00 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.1 | $1.1M | NEW | 200k | 5.73 |
|
| Nextcure Com New | 0.1 | $1.1M | NEW | 192k | 5.86 |
|
| Karyopharm Therapeutics Com New Call Option (KPTI) | 0.1 | $1.0M | 158k | 6.54 |
|
|
| Perspective Therapeutics Com New (CATX) | 0.1 | $1.0M | -71% | 300k | 3.43 |
|
| Arbutus Biopharma Call Option (ABUS) | 0.1 | $960k | +2174% | 212k | 4.54 |
|
| Sutro Biopharma (STRO) | 0.1 | $654k | 753k | 0.87 |
|
|
| Jade Biosciences Com New (JBIO) | 0.0 | $564k | 65k | 8.63 |
|
|
| Engene Holdings (ENGN) | 0.0 | $526k | 77k | 6.83 |
|
|
| Context Therapeutics (CNTX) | 0.0 | $390k | -22% | 403k | 0.97 |
|
| Repare Therapeutics Ord (RPTX) | 0.0 | $352k | 200k | 1.76 |
|
|
| Crescent Biopharma (CBIO) | 0.0 | $214k | -93% | 18k | 11.89 |
|
| Adagio Med Hldgs (ADGM) | 0.0 | $155k | 80k | 1.94 |
|
|
| Q32 Bio (QTTB) | 0.0 | $55k | 28k | 1.98 |
|
|
| Silverback Therapeutics (SPRY) | 0.0 | $25k | NEW | 2.5k | 10.05 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $3.0k | 75k | 0.04 |
|
Past Filings by Affinity Asset Advisors
SEC 13F filings are viewable for Affinity Asset Advisors going back to 2020
- Affinity Asset Advisors 2025 Q3 filed Nov. 13, 2025
- Affinity Asset Advisors 2025 Q2 filed Aug. 13, 2025
- Affinity Asset Advisors 2025 Q1 filed May 14, 2025
- Affinity Asset Advisors 2024 Q4 filed Feb. 13, 2025
- Affinity Asset Advisors 2024 Q3 filed Nov. 13, 2024
- Affinity Asset Advisors 2024 Q2 filed Aug. 14, 2024
- Affinity Asset Advisors 2024 Q1 filed May 14, 2024
- Affinity Asset Advisors 2023 Q4 filed Feb. 13, 2024
- Affinity Asset Advisors 2023 Q3 filed Nov. 14, 2023
- Affinity Asset Advisors 2023 Q2 restated filed Aug. 21, 2023
- Affinity Asset Advisors 2023 Q2 filed Aug. 14, 2023
- Affinity Asset Advisors 2023 Q1 filed May 15, 2023
- Affinity Asset Advisors 2022 Q4 filed Feb. 13, 2023
- Affinity Asset Advisors 2022 Q3 filed Nov. 14, 2022
- Affinity Asset Advisors 2022 Q2 filed Aug. 12, 2022
- Affinity Asset Advisors 2022 Q1 filed May 13, 2022